What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study

被引:9
|
作者
Shim, Geumsook [1 ]
Park, Hye Youn [1 ]
Jang, Joon Hwan [1 ]
Kim, Euitae [1 ]
Park, Hye Yoon [1 ]
Hwang, Jae Yeon [1 ,2 ]
Kim, Sung Nyun [1 ]
Jang, Go-Eun [3 ]
Kwon, Jun Soo [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea
[2] Seoul Natl Univ, Brain & Cognit Sci WCU Program, Coll Nat Sci, Seoul 110744, South Korea
[3] SNU MRC, Clin Cognit Neurosci Ctr, Neurosci Inst, Seoul, South Korea
关键词
escitalopram; high dose; obsessive-compulsive disorder; selective serotonin reuptake inhibitors; SEROTONIN REUPTAKE INHIBITORS; POSITRON-EMISSION-TOMOGRAPHY; SOCIAL ANXIETY DISORDER; DOUBLE-BLIND; PREFRONTAL CORTEX; 20; MG; PLACEBO; PHARMACOTHERAPY; DOPAMINE; TRANSPORTER;
D O I
10.1097/YIC.0b013e32834a5c09
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study explored the efficacy and tolerability of very high doses (maximum dose of >40 mg/day), high doses (maximum dose of 25-40 mg/day), and standard doses (maximum dose of <= 20 mg/day) of escitalopram (ESC) as an anti-obsessive-compulsive disorder treatment in a naturalistic clinical setting. We reviewed the medical records of all patients with obsessive-compulsive disorder (n = 246) who had taken ESC between May 2006 and September 2009, and assigned Clinical Global Impression (CGI) scores, retrospectively. Of the total sample, 24.4, 38.2, and 37.4% patients received very high, high, and standard doses of ESC, and the mean daily maximum doses of ESC were 57.3 +/- 12. mg, 33.9 +/- 5.4 mg, and 13.4 +/- 5.8 mg, respectively. The CGI-Severity scores in each group decreased significantly after treatment with ESC, as evidenced by response rates (i.e. CGI-Improvement scores of 1 or 2) of 46.3, 43.2, and 26.2%, respectively. Although some adverse events increased in a dose-dependent manner, most could be managed with an ESC dose adjustment. These results imply that doses less than or equal to 40 mg/day ESC are sufficient for symptomatic improvement with good tolerability for most patients. Very high doses of ESC, on the other hand, can be considered for patients with inadequate therapeutic responses to the administration of 40 mg/day ESC. Int Clin Psychopharmacol 26:284-290 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [41] Adequacy of treatment in outpatients with obsessive-compulsive disorder
    Cohen, S. E.
    Storosum, B. W.
    Vulink, N. C.
    De Koning, P. P.
    Namavar, Y.
    Zantvoord, J. B.
    Denys, D.
    COMPREHENSIVE PSYCHIATRY, 2025, 136
  • [42] Obsessive-Compulsive Disorder Advances in Diagnosis and Treatment
    Hirschtritt, Matthew E.
    Bloch, Michael H.
    Mathews, Carol A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (13): : 1358 - 1367
  • [43] Antipsychotic augmentation in the treatment of obsessive-compulsive disorder
    Thamby, Abel
    Jaisoorya, T. S.
    INDIAN JOURNAL OF PSYCHIATRY, 2019, 61 (07) : S51 - S57
  • [44] Pharmacologic treatment of obsessive-compulsive disorder comorbidity
    Pallanti, Stefano
    Grassi, Giacomo
    EXPERT OPINION ON PHARMACOTHERAPY, 2014, 15 (17) : 2543 - 2552
  • [45] Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults
    Roh, Daeyoung
    Jang, Ki Won
    Kim, Chan-Hyung
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2023, 21 (04) : 676 - 685
  • [46] Past, Present and Future Drugs for the Treatment of Obsessive-Compulsive Disorder
    Marazziti, D.
    Consoli, G.
    Baroni, S.
    Dell'Osso, M. Catena
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (29) : 3410 - 3421
  • [47] Maintenance treatment for obsessive-compulsive disorder: Findings from a naturalistic setting
    Peselow, Eric D.
    Pizano, Demetria R.
    Ishak, Waguih William
    ANNALS OF CLINICAL PSYCHIATRY, 2015, 27 (01) : 25 - 32
  • [48] Neuropsychological predictors of response to randomized treatment in obsessive-compulsive disorder
    D'Alcante, Carina C.
    Diniz, Juliana B.
    Fossaluza, Victor
    Batistuzzo, Marcelo C.
    Lopes, Antonio C.
    Shavitt, Roseli G.
    Deckersbach, Thilo
    Malloy-Diniz, Leandro
    Miguel, Euripedes C.
    Hoexter, Marcelo Q.
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2012, 39 (02): : 310 - 317
  • [49] Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial
    Feusner, Jamie D.
    Kerwin, Lauren
    Saxena, Sanjaya
    Bystritsky, Alexander
    PSYCHOPHARMACOLOGY BULLETIN, 2009, 42 (01) : 81 - 93
  • [50] Optimal management of pediatric obsessive-compulsive disorder
    Ung, Danielle
    Ale, Chelsea M.
    Storch, Eric A.
    PEDIATRIC HEALTH MEDICINE AND THERAPEUTICS, 2012, 3 : 9 - 18